Summary
41 / 100 · Bulios Score
What speaks for it
- The share price is below the Bulios Fair Price.
- It earns 6.6 USD a year on every 100 USD of invested capital.
What to watch
- The company made a loss over the last 12 months.
- It passes only 3 of the 9 points of the Piotroski financial health test.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks cheapBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
The company made a loss over the last 12 months, so there is no profit to set the price against.
Valuation in detailIs it growing?
It is shrinkingRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 3.2% a year over 5 years. Over the last 3 years it fell by 0.4% a year.
Growth in detailDoes it make money?
ReasonablyOver the last 12 months it made a loss of $4.73B.
Profitability in detailIs it financially healthy?
Debt is a burdenOver the last 12 months it spent more cash than it brought in. Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
Moderate, at risk- Yield
- 5.28%
- Raised in a row
- 4 years
You receive $1.55 per share a year. The payout is more than the company can comfortably cover.
Dividends in detailWhat do analysts expect?
Neutral- Buy 1
- Hold 2
- Sell 1
Today's price within the analysts' price targets
The average target of $39 is 34% above today's price. 25% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
By product
The company reports no revenue by product.
By region
The company reports no revenue by region.